2022 the Japanese Society of Medical Oncology Annual Meeting

Session information

Oral Session

[O19] Oral Session 19 Translational Research / Clinical Pharmacology
【E】

Sat. Feb 19, 2022 8:20 AM - 9:50 AM Room 13 (Gold Room, B2F, The Prince Kyoto Takaragaike)

Chair:Yuichi Ando(Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital),Yataro Daigo(Department of Medical Oncology and Cancer Center / Center for Antibody and Vaccine Therapy, Institute of Medical Science, Shiga University of Medical Science / The University of Tokyo)
Discussant:Shunsuke Kondo(Department of Experimental Therapeutics, National Cancer Center Hospital)

Yosuke Tanaka1, Fumiko Chiwaki2, Shinya Kojima1, Masahito Kawazu1, Masayuki Komatsu2, Toshihide Ueno1, Satoshi Inoue1, Shigeki Sekine3, Keisuke Matsusaki4, Hiromichi Matsushita5, Narikazu Boku6, Yae Kanai7, Yasushi Yatabe3, Hiroki Sasaki2, Hiroyuki Mano1 (1.Division of Cellular Signaling, National Cancer Center Research Institute, 2.Department of Translational Oncology, National Cancer Center Research Institute, 3.Department of Diagnostic Pathology, National Cancer Center Hospital, 4.Kanamecho Hospital, 5.Department of Laboratory Medicine, National Cancer Center Hospital, 6.Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 7.Department of Pathology, Keio University School of Medicine)

Hideyuki Hayashi1, Shigeki Tanishima2, Kaori Mochida1, Tomoka Fujikura1, Sachiko Hagiwara1, Emmy Yanagita1, Hiroshi Yamada1, Ryutaro Kawano1, Kohei Nakamura1, Marin Ishikawa1, Yasutaka Kato1, Eriko Aimono1, Mitsuho Imai1, Arisa Ueki1, Hiroshi Nishihara1 (1.Genomics Unit, Keio Cancer Center, Keio University School of Medicine, 2.Department of Biomedical Informatics Development, Mitsubishi Space Software Co., Ltd)

Shunji Takahashi1, Nobumasa Mizuno2, Kosei Hasegawa3, Koji Matsumoto4, Shirong Han5, Tsutomu Takatsuki6, Fan Jin7, Kazuhiko Nakagawa8 (1.Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 2.Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan, 3.Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan, 4.Division of Medical Oncology, Hyogo Cancer Center, Hyogo, Japan, 5.Biostatistics and Research Decision Sciences, MSD K.K, Tokyo, Japan, 6.Clinical Development, MSD K.K, Tokyo, Japan, 7.Clinical Development, Merck & Co., Inc., Kenilworth, NJ, USA, 8.Department of Medical Oncology, Kindai University Hospital, Osaka, Japan)

Santiago Ponce Aix1, Emiliano Calvo2, Victor Moreno3, Guzman Alonso4, Andres Cervantes5, Suresh S. Ramalingam6, Jose Trigo7, Patricia Lorusso8, Muhammad Furqan9, Daniel Cho10, Alexander Muik11, Eleni Lagkadinou11, Özlem Türeci11, Nora Pencheva12, Ulf Forssmann11, Ugur Sahin11, Tahamtan Ahmadi13, Brandon Higgs13, Maria Jure-Kunkel13, Ignacio Melero14 (1.Hospital Universitario 12 de Octubre, Madrid, Spain, 2.START Madrid-CIOCC, Madrid, Spain, 3.START Madrid-FJD, Hospital Fundación Jiménez Díaz, Madrid, Spain, 4.Vall d’Hebron Institute of Oncology, Barcelona, Spain, 5.University Hospital of Valencia, Valencia, Spain, 6.Winship Cancer Institute of Emory University, Atlanta, GA, USA, 7.Hospital Universitario Virgen de la Victoria, Málaga, Spain, 8.Yale Cancer Center, New Haven, CT, USA, 9.University of Iowa, Iowa City, IA, USA, 10.NYU Langone Health Tisch Hospital, New York, NY, USA, 11.BioNTech SE, Mainz, Germany, 12.Genmab A/S, Copenhagen, Denmark, 13.Genmab, Princeton, NJ, USA, 14.Clinica Universidad de Navarra, Pamplona, Spain)